کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3978454 1257280 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Acétate d'abiratérone (AA) : comment prescrire l'abiratérone et à qui en 2014 ?
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Acétate d'abiratérone (AA) : comment prescrire l'abiratérone et à qui en 2014 ?
چکیده انگلیسی
Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion. In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000 mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Based of these results, AA is approved in metastatic CRPC patients in post-docetaxel setting or pre-docetaxel setting in 2013.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bulletin du Cancer - Volume 101, Issue 4, April 2014, Pages 388-393
نویسندگان
, , , ,